Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree wholeheartedly!
We have to proactively report bias potential in my line of work with any research we present.
Politicians are supposed to do it, but do not.
Journalists need to do it.....otherwise they just spin false or biased information to the masses.
You wrote: As for true journalism, I don't think that exists anymore. The media is all about ratings and selling papers.
Amen, sister...Amen!!!! Thats where all the money goes when people contribute to the candidates....and the media sucks it up by continuing to find or make up dirt on the candidates.....Fairness in jounalism is what we should demand....or just shut off the TV!
Not saying that another 4 years of Republicans will be any better....(besides, listening to politicians is a mark of insanity, because they keep saying the same things over and over and WE keep believing them, whether they are good orators or POWs, Cheat on their wives or can't say "Nuclear"....)
All I am saying is that it CAN be worse! A lot worse. I hope it can be better, but lets not fool ourselves-politicians say what they think we want to hear and somehow, most of a group of voters on both sides somehow believe the verbage/garbage extruding from their mouths---they always say "I will do this, and I will do that...." but they never say how they will do something or how much it will cost! We somehow believe them based on appearance or past voting records (If we have some records more than 143 days old....) and we somehow appear appalled when politicians end up not doing something they promised.....JMHO
And we should have truth in media: all journalists should state their bias up front in every article or interview---it would help control the liberal / right wing media bias...IMHO, of course!
Yes it can! No guarantee, but it can always get worse.....
Depression/Homelessness/Illness/Suicide Bombers in America
It can always get worse!
Still not much activity...it will still be a separate company from KCI but indelibly linked....
any interest in LifeCell?
Unfortunately, stories like these are true....in the Emergency Department you cannot make this stuff up.....
Tsurge
Trying times at the FDA....this is so true. At the hospital we always use the meds thinking they are safe. Many protocols and checks and balances are in process now to prevent mistakes in giving out medicines....you don't ever think they are not made safely!!! FDA has gone in to many American pharma plants and shut down production to mandate safety in manufacturing....FDA is now going to have to go to the suppliers (i.e. China) and find out if the "recipes" and ingredients are safe!
Welcome aboard jap1511. Its been too quiet around here, especially for a company like KCI. They probably spent a little too much for Lifecell, but when the chips fall, and KCI gets into Asia AND Lifecell uses the KCI marketing arm, well, IMO, watch them move. Good one getting in on the dip.
Again, welcome aboard.
Tsurge
I agree...It will be a steal for GSk....
TSURGE
Finally approved. What a jump!
sorry, I was out of town...and not logged on....
do you think it will keep going higher back to near what it was a year ago?
If its pipeline keeps producing, it should....
great leap...
tsurge
grantg2,
I updated the LIFECELL AND KCI board's iBoxes....
have been keeping my "ears to the ground" with my peeps and everything I hear is that it is a great deal all around. Especially for LifeCell mainly for the International distribution of LifeCell's products in Asia and Europe. Especially with LifeCell's new product Strattice.
Will fill in more as I find out more....
TSURGE
PL1, hope all is well. Here is some new information on a MS Biotech Research:
From RTTnews:
MediciNova Reports Positive Results For MN -166 In Two Year Phase II Clinical Trial In Patients With Multiple Sclerosis - Update [MNOV]
4/7/2008 7:46:32 AM San Diego, California - based biopharmaceutical company MediciNova Inc. (MNOV) announced positive clinical results for the two year Phase II clinical trial of orally administered MN-166 for the treatment of multiple sclerosis. The trial reported slowing of disability progression and significant neuroprotective effects. Multiple sclerosis is an autoimmune condition in which the immune system attacks the central nervous system that leads to numerous physical and mental symptoms, and often progresses to physical and cognitive disability.
The company reported a significantly less sustained disability progression in patients who received MN-166 at either 30 mg or 60 mg per day for 24 months compared to those who have completed 12 months. Radiological measures corroborated the findings.
Further, the significant reduction in brain volume loss was observed in patients on 60 mg per day for 24 months compared to other treatment groups. Earlier, the company has noted that those on 60 mg per day of the compound for 12 months has less reduction in brain volume compared to placebo. The relative risk of neuronal loss that converts new inflammatory lesions identified at month two to persistent black holes were comparatively less in patients on 30 mg per day.
The orally administered compound was tried on a randomized, double blind, placebo controlled trial. The company said, MN-166 tolerated at all doses during the 24-month period. 297 patients were enrolled for the phase II trial and 245 patients completed the two-year term.
The company said its Scientific Advisory Board has recommended for advancing MN-166 into pivotal-design studies with clinical and MRI evaluations of Multiple Sclerosis progression as the primary objective.
The company announced the outcome of the first year Phase 1 trial results earlier in March 2007. However, the year one study has failed to significantly reduce cumulative brain lesion count on MRI, which was the protocol-defined primary endpoint of the study.
MNOV finished Friday's regular trading session at $4.00, up $0.40 on a volume of 1,10 shares.
TSURGE
I am moderator of the Lifecell board, though VERY little action on it....minimal if any visits....
I have not updated the ibox on it with their new product Strattice (trademark)....
Will be glad to fill in on what I know and have learned in using it in my other job....as well as what I have learned from researching the products produced by Lifecell and other competitors...
TSURGE
Interesting isn't it....KCI announced that they are buying Lifecell....smart move by KCI...not necessarily a great move by Lifecell...Lifecell is a smaller company but extremely well run by P. Thomas. Has excellent scientific and research and marketing base. As long as they keep the process intact, it will be a smart move by both companies......!!!!
Interesting isn't it....KCI announced that they are buying Lifecell....smart move by KCI...not necessarily a great move by Lifecell...Lifecell is a smaller company but extremely well run by P. Thomas. Has excellent scientific and research and marketing base. As long as they keep the process intact, it will be a smart move by both companies......!!!!
I agree, this info may be troubling. I know of a friend who just went to work for a rival company of KCI...(Smith and Nephew). He says they are working to improve their rival product for wounds to compete more readily with KCI's product.
I do realize that KCI's research and development department is strong and continues to work on new products.....also, it will be interesting to see if KCI buys or is bought, just like its rival, Blue Sky----not trying to initiate rumors, just IMO it is a possibility....
TSURGE
I have added information from MedTech1.com website to the iBOX.
PL1,
even though I am a trauma surgeon, I am a believer in the anti-inflammatory effects of omega-3 fatty acids! There actually have been some studies of their use in ICU's to reduce pneumonias, ARDS, etc. Again thank you for such great information! By the way, I have told several of my colleagues about IHUB and especially this site! I am glad you present this information for all of us.
thanks
TSURGE
Hey there,
COLY turned out ok....
But EPGL looks great if we can just get some momentum going...with such a real company doing such real things for real people, well, there is a reason we all like it so much...the potential is too great to ignore....
OT: It is going well...have been on coast of the Carolinas in 65-70 degree sunshine until yesterday when this arctic blast from your area just pushed the temps down....so tonight will be a warm 18 degees...too cold for this area..we don't have enough ice to drive our cars onto the ocean for ice fishing (LOL)like you all do on the lakes up there....next week it will be getting back to the high 60s again....yeah!
Jimmym4,
I agree with you! There is a great need for their services in this society today! OT: by the way, great Ice fishing picture! How cold is it there?
Tsurge
PL1,
Thank you for putting this on your site....
As you know, most of Civilian Trauma care improvement has risen out of almost all Military conflicts throughout history....(in fact, being on call last night, dealing with several Gun shot wounds, Knife wounds, and blunt force motor vehicle crashes---there is no such thing as an accident...any one can see there are many similarities and the critical care management of these patients has allowed the murder rate and motor vehicle deaths to be lower than ever before in most cities!)...
Many of the authors of the NEJM article are counterparts of mine and a few(Trunkey, Moore, etc.) are the Godfathers of Trauma care and the instigators of Surgical Critical Care.....they helped develop the programs for the care of the injured patient...
The current military conflict, regardless of a person's political perspective, shows how military trauma care and civilian trauma care are indelibly linked and have "learned from each other." This is even more evident with the medical treatment for severe coagulopathy (bleeding) from the "triad of death": acidosis-hypothermia-and coagulopathy....Factor VII...
we use factor VII frequently, even though it is not yet approved for use by the FDA for trauma care and it is very expensive (i.e. a hospital will usually not get remimbursed for the treatment, since it is not yet FDA approved)...we use it because it works and I personally know it has saved several of my patients by "shutting down" the coagulopathy that develops even after all surgical bleeding has been stopped....
the use of protocols and process improvement initiatives shows how an organized trauma system can impact care by constantly evaluating outcomes and making changes in the process of care...this is what the American College of Surgeons Committee on Trauma (ACS-COT) Verification process oversees to allow a city's trauma center to be Nationally verified as a Level 1 trauma center (although most states have their own verification process, they are not as stringent as the American College of Surgeons Verification Process)....as an example, in NC there are 5 state level-1 trauma centers, but until recently we were the only national ACS-COT Verified Level-1 trauma center....which is evaluated every three years by the ACS-COT....
Sorry to be long winded....just got going after reading the NEJM article....Thanks again, PL1
Everyone have a safe and happy New Year...
FYI,
this is from Seeking Alpha....
I have experience with these products if anyone ever wants info from experienced user of wound therapy.....
Kinetic Concepts Likely to Lose Its Patents, and Its Value - Barron's
by SA Editor Eli Hoffmann
Despite technology that has revolutionized how hospitals treat chronic skin lesions, Barron's says Kinetic Concepts' (KCI) shares are dead money due to the likelihood of its inability to enforce its patents.
KCI produced $1.4 billion in revenue last year largely on the heels of its negative-pressure VACs that suction wounds, preventing bacteria from gathering, reducing swelling and promoting cell growth. Negative-pressure treatments are already used on 1/3 of chronic wounds in the U.S. and about 20% worldwide. KCI bills Medicare $1,700/month for each VAC system. With gross margins at near 50%, KCI's projected 2008 EPS of $3.30 means its shares trade at just 15x earnings, vs. 20x for similar companies, as investors fret the sustainability of its business.
Last year a federal judge ruled two rivals didn't infringe on its patents, subsequent to which British med-supply giant Smith & Nephew (SNN) bought one of them; it plans a Jan. 2008 launch of a VAC competitor. Another rival has produced a similar, cheaper product. It contends KCI's patents aren't valid due to pre-existing public-domain research, information which a previous head of KCI research has told courts the company was aware of. The U.S. Patent and Trademark Office has opened a re-examination into whether the Wake Forest patent bought by KCI should be invalidated as 'prior art.'
TSURGE
PL1,
sorry I have been incommunicato recently...I have been on clinicals alot the last two weeks and I got a virus in my PC that has caused problems with me getting on IHUB much...
some info on KCI that I thought prudent....I have experience with these products if you or anyone want info...also there is a KCI board that I assist managing with Grantg2...this is from Seeking Alpha....
Kinetic Concepts Likely to Lose Its Patents, and Its Value - Barron's
by SA Editor Eli Hoffmann
Despite technology that has revolutionized how hospitals treat chronic skin lesions, Barron's says Kinetic Concepts' (KCI) shares are dead money due to the likelihood of its inability to enforce its patents.
KCI produced $1.4 billion in revenue last year largely on the heels of its negative-pressure VACs that suction wounds, preventing bacteria from gathering, reducing swelling and promoting cell growth. Negative-pressure treatments are already used on 1/3 of chronic wounds in the U.S. and about 20% worldwide. KCI bills Medicare $1,700/month for each VAC system. With gross margins at near 50%, KCI's projected 2008 EPS of $3.30 means its shares trade at just 15x earnings, vs. 20x for similar companies, as investors fret the sustainability of its business.
Last year a federal judge ruled two rivals didn't infringe on its patents, subsequent to which British med-supply giant Smith & Nephew (SNN) bought one of them; it plans a Jan. 2008 launch of a VAC competitor. Another rival has produced a similar, cheaper product. It contends KCI's patents aren't valid due to pre-existing public-domain research, information which a previous head of KCI research has told courts the company was aware of. The U.S. Patent and Trademark Office has opened a re-examination into whether the Wake Forest patent bought by KCI should be invalidated as 'prior art.'
TSURGE
Grantg2
Yes, the problems with PCs. My wife has a Mac for her work and that is what I am using right now, until I get my computer back from Geeksquad (they are cleaning it up again). My next computer will truly be a Mac if I can swing it...
I do not know much, but I do know, from DD that their CEO is from like Johnson &Johnson and it is now starting to act like a Pharma though it is an equipment company. there has been speculation/rumor among the hospital staff and wound nurses that they are going to reorganize the sales and management forces, USA and International. In what way I do not know, but I do know I do not see as many reps at the hospital like I used to see, whatever that means! Could it mean they are combining their sales forces and streamlining them??? do not know. It could also mean they are just paring back...or that I have been too busy at work to see them. I do know when we set up the Rotoprone beds, they were very helpful and they do have a wonderful support group and delivery system for their Rotoprone.
I agree they are a good company with good products (I know because I use them, and use them a lot!!!). I am worried that like many medical companies, they may get caught up in the "Big Pharma" mentality....
I am also wondering if they are either getting ready to buy a company or getting ready to be bought up by one!!! why would their CEO be from Johnson and Johnson? just a guess and only IMO, but one I can't shake as a strong possibility!
Would Johnson and Johnson be interested in buying them??? I emphasize, this is only my speculation and fantasy...johnson and johnson has bought up many product companines in the past....
They have a strong R&D and just came out with an "Info- VAC" a vaccuum device that can measure store pics of wounds and download the info to a medical record or print it out....my only concern is if it is worth the additional cost...most of us take pics of complex wounds now and download them to our computers (the office ones with the elect medical record) and do not have to worry about a proprietary machine and coming back to a patients room to get the info...it may be more of a benefit for outpatient and nursing homes....I have not used it yet, so I can only speculate!
TSURGE
grantg2,
sorry for the late response. I have had a virus, in my computer that is, and have not been able to get on ihub for a while.
though the rotoprone is not an iron lung, I agree it sure does look like it...
I actually used it on 2 patients this past two weeks with great results. I feel if used early and appropriately, it can work.
I hope you had a great T Day, and hope you are having a great holiday time.
thanks for inviting me to the board.
tsurge
grantg2,
Have added some things on the IBOX...let me know what you think...
TSURGE
FYI......thought you may find this interesting....
http://seekingalpha.com/article/54618-genentech-s-avastin-slows-down-brain-cancer-study?source=i_email
Genentech's Avastin Slows Down Brain Cancer - Study
by SA Editor Judith Levy
Genentech's Avastin medication has been shown in a study to slow down the spread of brain tumors, the company announced Monday at a meeting of the Society for Neuro-Oncology in Dallas. Brain tumors are notoriously resistant to treatment. The study involved 167 patients with relapsed glioblastoma, an aggressive brain cancer with a life expectancy of three to six months and a 3% five-year survival rate. The tumors of 36% of subjects who took Avastin were stable for six months, well beyond the 15% result of patients on other medications in previous studies. Patients who took a combination of Avastin and the chemotherapy agent irinotecan did even better, with 51% showing stable tumors. "These findings exceeded our expectations," said Hal Barron, Genentech's SVP of development. Timothy Cloughesy, director of the Neuro-Oncology program at the University of California, concurred: "The findings suggested that at six months, more patients had lived without their cancer advancing when Avastin was administered as a single agent or in combination with chemotherapy than what we would normally expect." Avastin works by cutting off the tumors' blood supply. The drug, which brought in sales of $1.75 billion in 2006, is currently approved for use in lung and colon cancer and is being tested against 20 other kinds of cancer.
FYI
Information about Biogen IDEC drug:
http://sanantonio.bizjournals.com/triangle/stories/2007/11/05/daily45.html
Friday, November 9, 2007
Biogen Idec drug shows promise as rheumatoid arthritis treatment
Triangle Business Journal
Biogen Idec's new treatment for autoimmune diseases is showing promise in patients with rheumatoid arthritis, the company said Friday.
The drug, known as baminercept, generated clinically meaningful improvements in patents who took part in the phase II trial.
Biogen (Nasdaq: BIIB), a biotech firm headquartered in Massachusetts with 750 employees in the Triangle, said the results were promising enough to advance to two more mid-stage human clinical trials, which will test the drug in combination with another treatment in patients with moderate to severe rheumatoid arthritis for whom other treatments haven't worked.
Biogen presented the trial results at the American College of Rheumatology's 73rd annual meeting in Boston.
Rheumatoid arthritis is an autoimmune disease that causes immune cells to malfunction and attack the joints. Patients suffer intense pain, chronic inflammation, and destruction of cartilage, tendons and bones.
The announcement highlights Biogen's drug pipeline at a time when, according to a Financial Times report, possible buyers for the company are being asked to submit bids by next week. Biogen, whose flagship products are the non-Hodgkin's lymphoma treatment Rituxan and the multiple sclerosis drug Avonex, formally put itself up for sale in October after months of speculation.
Thought this may be interesting....
Biovail Optimistic On Approval For Depression Drug Launch
by FP Trading Desk
Biovail Corp. (BVF) remains optimistic that approval of its once daily treatment option for depression – affectionately known as BVF-033 or Wellbutrin Salt – is just around the corner, despite not yet hearing back from the FDA regarding the classification of Biovail's response to a non-approval letter received on Oct. 24, 2007.
According to RBC Capital analyst Douglas Miehm, Biovail said they had expected to hear back from the FDA already, but based on discussions with the agency, the company still fully expects to receive a class I review very shortly.
"In the event of a class I, approval would be expected with 60 days of submission or by the end of the year. Mr. Miehm informed clients in a note that adding a class II review would mean approval within six months or by the end of April 2008.
The company indicated it continues to negotiate with potential partners and expects to sign a deal before approval or shortly after in order to get the product on the market as quickly as possible.
Mr. Miehm said the difference between a class I and class II review in terms of the company's earnings per share in 2008 is only US2¢. More impactful to earnings would be the January launch of a generic 150mg Wellbutrin XL.
Currently, a conditional agreement is in place that states generic versions can not be launched until May 30, 2008, however an appeal made by generic drug maker, Anchen Pharmaceuticals, to the US appellate court could result in an earlier launch if successful.
A January launch compared to June would cost the company US32¢ to US34¢ in EPS, Mr. Miehm told clients, however, he added that the company's cost containment initiatives would more than offset this decrease.
Mr. Miehm's 2008 EPS remains unchanged at $1.47 as a result, while his 2007 EPS increases from $1.76 to $1.82.
His "outperform" rating and C$24 price target on the stock remain unchanged.
http://seekingalpha.com/article/53774-biovail-optimistic-on-approval-for-depression-drug-launch?source=i_email
PL1,
Great article...one of the problems with MRSA in the community is multi-factorial...primarily the "Hyper-hygeine" model...meaning too much cleanliness in children with anti-bacterial soaps and sprays....the young immune system is still trying to learn and ends up not being able to fight bacteria efficiently (and thus leads to auto-immune problems and potentially super- infections...however....
IMO- the main reasons we are seeing this super-bug spread are:
1. too many anti-biotics in the food/poultry processing of the world
2. over prescribing of antibiotics for the least cold or sniffle or viral symptoms (which antibiotics will not treat viral conditions) (patients are almost demanding something when they see their primary care MD
3. poorer nutrition (i.e. appropriate dietary habits as opposed to fast food mentality) across the country--though this is less likely except in the extreme patient populations....i.e. young and old patients....again, IMO....
thanks
tsurge
grantg2
I agree with you...has global potential especially winning the lawsuit last year (in Europe) against Blue Sky (now with Smith and Nephew), currently its only wound competitor for "negative pressure therapy"...
if it gets its research and development going further with a strong growth factor supplement for wounds and/or has the potential to buy another company for expansion into other products, then I think it will go way higher....if it gets to 80s then it may go to 120s....
but perhaps you are right about shorting....even the "hedgers" love to short a company like this just to keep it down...
let me know if I can ever help with this board...
tsurge
grantg2,
I agree with you...this is a great company with more than just the wound products....i.e. the rotoprone kinetic bed, and a great research and development program....
have used their products many times and they do help patients...the only thing they have needed is better organization and management (it seems they are acheiving it with new upper management...IMO).....
Let me know what you still think about this stock....
I almost started a KCI board myself last year...I am surprised more people don't get on board with it....
TSURGE
Lifecell is still going up...25% over last 3 months...
great products and excellent research and developmenent...
FYI.....when CMS is cutting reimbursements across the board, this tells me this technique is meaningful if they are allowing increasing CMS payments....
http://seekingalpha.com/article/53375-biosphere-medical-hopes-cms-decision-will-influence-third-party-payers?source=i_email
Effective January 1, 2008, the Centers for Medicare and Medicaid Services [CMS] will increase its hospital outpatient reimbursement for uterine fibroid embolization [UFE] by 113 percent to $5,639 per procedure.
The ruling was good news for BioSphere Medical (BSMD) and its bioengineered microsphere technology. Microspheres, cleared by the FDA in April 2000, are injected through a catheter into the blood vessels that feed target areas – such as uterine fibroids. By selectively blocking the target tissue’s blood supply, the deprived tissue will either be destroyed or become devitalized, resulting in therapeutic benefit.
While most women seeking UFE are not Medicare beneficiaries, BioSphere believes that CMS payment decisions may influence other third-party payers. The company anticipates industry-wide adjustments that are reflective of the CMS decision. On average, the dollar amount of third-party payer payments for UFE is 33 percent greater than the dollar amount of CMS payments.
Richard Faleschini, President and Chief Executive Officer of BioSphere Medical, commented,
We believe that providers, payers, and employers also benefit from the clinical and quality-of-life advantages of UFE, and that these benefits can translate into favorable economics for all constituents. Thus, we plan to press ahead with our messaging to hospitals about the benefits of UFE, and with our ongoing strategy to have UFE included among first-line therapy options for women with symptomatic fibroids.
This is an excellent post PL1, just like all of your other posts....
If this study pans out in humans (though a ways off), then it would revolutionize our trauma care....this would truly improve people's lives!!!
Thanks for all of your information, PL1
here are a couple of new IPO's in health care....from a Seeking Alpha site....
http://seekingalpha.com/article/52783-two-healthcare-ipos-bioform-medical-the-ensign-group
Two Healthcare IPOs: BioForm Medical, The Ensign Group
by Abbi Adest, (Seeking Alpha)
There are two healthcare IPOs this week: BioForm Medical (BFRM), a medical aesthetics company that markets a dermal filler to treat facial wrinkles and volume loss; and The Ensign Group, Inc. (ENSG), a company that provides skilled nursing and rehabilitative care services through 60 skilled nursing facilities in 6 states.
BIOFORM MEDICAL (BFRM)
Business Overview (from prospectus)
We are a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient’s appearance. Our core product is Radiesse, an injectable dermal filler designed to provide long-lasting, cost-effective and safe aesthetic improvement for patients. Our clinical studies have demonstrated that Radiesse provides meaningful initial aesthetic correction and approximately 12 months’ duration of aesthetic improvement in many patients, resulting in high patient satisfaction. Physicians have used Radiesse for more than five years, and, we have shipped over 500,000 syringes worldwide.
THE ENSIGN GROUP, INC. (ENSG)
Business Overview (from prospectus)
We are a provider of skilled nursing and rehabilitative care services through the operation of facilities located in California, Arizona, Texas, Washington, Utah and Idaho. As of September 30, 2007, we owned or leased 61 facilities. All of our facilities are skilled nursing facilities, except for four facilities that offer both skilled nursing and assisted living arrangements in a campus setting, and three stand-alone assisted living facilities. At our facilities, each of which strives to be the facility of choice in the community it serves, we provide a broad spectrum of skilled nursing and assisted living services, physical, occupational and speech therapies, and other rehabilitative and healthcare services, for both long-term residents and short-stay rehabilitation patients. Our facilities have a collective capacity of over 7,400 skilled nursing, assisted living and independent living beds. As of September 30, 2007, we owned 23 of our facilities and operated an additional 38 facilities under long-term lease arrangements with options to purchase 12 of those 38 facilities. We also have entered into agreements to purchase four of the 38 facilities that we operate under long-term lease arrangements, which are pending subject to certain closing conditions. For the year ended December 31, 2006 and the six months ended June 30, 2007, our skilled nursing services, including our integrated rehabilitative therapy services, generated approximately 97% of our revenue.
You are welcome, PL1....hope you don't mind my adding my "2 cents" worth on some of the topics.....
I also may have some new itemsproducts that are coming thru the hospitals that I or my colleagues have used or know about, that I may comment on....
one of those is the new rendition of the "ON-Q"pain pump( by I-Flow Corp---iflo 17.81) for postoperative pain(basically is a continual numbing catheter at site of the incision)....i used one the other day with a partner and it took the pain away so the patient did not have to use any pain meds that could add additional time in the hospital.....very impressed with results and the patient was even more happy...
just some "2-cents" worth....
TSURGE
Of interest, abnormal ion channels are increasingly being linked to diseases in humans....especially in the neuro and cardio areas....may have something to do with the changes in lipo-polysaccharide portion of cell and organelle membranes...and these can be influenced by short chain fatty acids (saturated fats) vs. longer poly-unsaturated and omega 3 fatty acid chains......INTERESTING....
PL1,
finally getting to look at the boards after a rough week...
this is a promising technique....I remember in Medical School discussing this "theory", and yes back in the early '80s it was just a theory, with our biochemistry and pathology professors....this was along the lines of their work on monoglonal antibodies and attaching potential chemo and radiation particles to the antibodies....well, guess their theories turned out to work...
great to see it working....24 years later!
great site you have here!
TSURGE
PL1,
Thanks. Great advice and I hope you and yours had a great weekend....I was able to spend time with family and get more refreshed. Got to assist at Uptown at the Discovery Place Museum showing "Body Worlds" at the museum.....Excellent show that brought a lot of interest about the human body and medicine....
Take Care and Blessings....
TSURGE